vs
Side-by-side financial comparison of Bank First Corp (BFC) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
Bank First Corp is the larger business by last-quarter revenue ($44.9M vs $38.3M, roughly 1.2× ImmunityBio, Inc.). Bank First Corp runs the higher net margin — 45.8% vs -161.8%, a 207.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 12.1%). Bank First Corp produced more free cash flow last quarter ($51.0M vs $-71.3M).
First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
BFC vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $38.3M |
| Net Profit | $18.4M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | 51.0% | -169.0% |
| Net Margin | 45.8% | -161.8% |
| Revenue YoY | 12.1% | 407.0% |
| Net Profit YoY | 4.8% | -4.7% |
| EPS (diluted) | $1.87 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $38.3M | ||
| Q3 25 | $44.2M | $32.1M | ||
| Q2 25 | $41.6M | $26.4M | ||
| Q1 25 | $43.1M | $16.5M | ||
| Q4 24 | $40.1M | $7.6M | ||
| Q3 24 | $40.8M | $6.1M | ||
| Q2 24 | $38.9M | — | ||
| Q1 24 | $37.7M | — |
| Q4 25 | $18.4M | $-61.9M | ||
| Q3 25 | $18.0M | $-67.3M | ||
| Q2 25 | $16.9M | $-92.6M | ||
| Q1 25 | $18.2M | $-129.6M | ||
| Q4 24 | $17.5M | $-59.2M | ||
| Q3 24 | $16.6M | $-85.7M | ||
| Q2 24 | $16.1M | — | ||
| Q1 24 | $15.4M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 51.0% | -169.0% | ||
| Q3 25 | 50.8% | -173.5% | ||
| Q2 25 | 49.7% | -269.8% | ||
| Q1 25 | 51.3% | -390.1% | ||
| Q4 24 | 54.4% | -919.0% | ||
| Q3 24 | 50.7% | -1314.3% | ||
| Q2 24 | 51.0% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 45.8% | -161.8% | ||
| Q3 25 | 40.7% | -209.8% | ||
| Q2 25 | 40.5% | -350.3% | ||
| Q1 25 | 42.3% | -784.9% | ||
| Q4 24 | 49.3% | -783.4% | ||
| Q3 24 | 40.6% | -1404.0% | ||
| Q2 24 | 41.3% | — | ||
| Q1 24 | 40.8% | — |
| Q4 25 | $1.87 | $-0.06 | ||
| Q3 25 | $1.83 | $-0.07 | ||
| Q2 25 | $1.71 | $-0.10 | ||
| Q1 25 | $1.82 | $-0.15 | ||
| Q4 24 | $1.75 | $-0.08 | ||
| Q3 24 | $1.65 | $-0.14 | ||
| Q2 24 | $1.59 | — | ||
| Q1 24 | $1.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $243.2M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $643.8M | $-500.5M |
| Total Assets | $4.5B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $243.2M | $242.8M | ||
| Q3 25 | $126.2M | $257.8M | ||
| Q2 25 | $120.3M | $153.7M | ||
| Q1 25 | $300.9M | $61.6M | ||
| Q4 24 | $261.3M | $149.8M | ||
| Q3 24 | $204.4M | $130.4M | ||
| Q2 24 | $99.0M | — | ||
| Q1 24 | $83.4M | — |
| Q4 25 | $643.8M | $-500.5M | ||
| Q3 25 | $628.1M | $-524.3M | ||
| Q2 25 | $612.3M | $-570.7M | ||
| Q1 25 | $648.4M | $-591.4M | ||
| Q4 24 | $639.7M | $-489.1M | ||
| Q3 24 | $628.9M | $-745.1M | ||
| Q2 24 | $614.6M | — | ||
| Q1 24 | $609.3M | — |
| Q4 25 | $4.5B | $501.9M | ||
| Q3 25 | $4.4B | $519.0M | ||
| Q2 25 | $4.4B | $402.1M | ||
| Q1 25 | $4.5B | $303.8M | ||
| Q4 24 | $4.5B | $382.9M | ||
| Q3 24 | $4.3B | $364.6M | ||
| Q2 24 | $4.1B | — | ||
| Q1 24 | $4.1B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.5M | $-70.4M |
| Free Cash FlowOCF − Capex | $51.0M | $-71.3M |
| FCF MarginFCF / Revenue | 113.6% | -186.2% |
| Capex IntensityCapex / Revenue | 25.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 3.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $75.8M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.5M | $-70.4M | ||
| Q3 25 | $15.5M | $-68.9M | ||
| Q2 25 | $11.9M | $-79.7M | ||
| Q1 25 | $6.2M | $-85.9M | ||
| Q4 24 | $65.8M | $-85.1M | ||
| Q3 24 | $18.8M | $-98.8M | ||
| Q2 24 | $14.9M | — | ||
| Q1 24 | $1.3M | — |
| Q4 25 | $51.0M | $-71.3M | ||
| Q3 25 | $12.5M | $-69.6M | ||
| Q2 25 | $8.2M | $-80.8M | ||
| Q1 25 | $4.0M | $-87.0M | ||
| Q4 24 | $58.6M | $-87.3M | ||
| Q3 24 | $16.9M | $-101.6M | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $551.0K | — |
| Q4 25 | 113.6% | -186.2% | ||
| Q3 25 | 28.2% | -217.2% | ||
| Q2 25 | 19.8% | -305.9% | ||
| Q1 25 | 9.3% | -526.9% | ||
| Q4 24 | 146.3% | -1155.4% | ||
| Q3 24 | 41.5% | -1663.2% | ||
| Q2 24 | 35.3% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | 25.5% | 2.4% | ||
| Q3 25 | 6.7% | 2.3% | ||
| Q2 25 | 8.7% | 4.1% | ||
| Q1 25 | 5.0% | 6.8% | ||
| Q4 24 | 18.0% | 28.0% | ||
| Q3 24 | 4.5% | 45.7% | ||
| Q2 24 | 3.1% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | 3.40× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 3.75× | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 0.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
